ESTRACYT

This brand name is authorized in Estonia, Spain, France, Japan, Netherlands, Singapore, Turkey, United Kingdom

Active ingredients

The drug ESTRACYT contains one active pharmaceutical ingredient (API):

1 Estramustine phosphate sodium UNII MUZ9585Y7B - ESTRAMUSTINE PHOSPHATE

Estramustine is a chemical compound of oestradiol and nitrogen mustard. It is effective in the treatment of advanced prostatic carcinoma. Estramustine has a dual mode of action. The intact molecule acts as an anti-miotic agent; after hydrolysis of the carbamate ester, the metabolites act to bridge the released oestrogens and exert an anti-gonadotrophic effect. Read about Estramustine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ESTRACYT Capsule	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XX11	Estramustine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1021161, 1778935
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 54190
Country: FR	Base de données publique des médicaments	Identifier(s): 60675618
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 39652
Country: JP	医薬品医療機器総合機構	Identifier(s): 4219003M1054
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 2518
Country: SG	Health Sciences Authority	Identifier(s): 09464P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8681308151018